Search Results

You are looking at 221 - 230 of 493 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Multimodality Approaches for the Curative Treatment of Esophageal Cancer

Raymond Jang, Gail Darling, and Rebecca K.S. Wong

with clinical stage T1N1 or T2–3N0–1 disease were eligible, and were randomized to either 41.4 Gy of radiotherapy over 5 weeks with concurrent weekly carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) followed by surgery, or to surgery

Full access

NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022

Featured Updates to the NCCN Guidelines

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Brian C. Baumann, Jeremy Bordeaux, Pei-Ling Chen, Robert Chin, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Roy C. Grekin, Kelly Harms, Alan L. Ho, Ashley Holder, John Nicholas Lukens, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Soo Park, Tejesh Patel, Igor Puzanov, Jeffrey Scott, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, William Stebbins, Valencia Thomas, Yaohui G. Xu, Beth McCullough, Mary A. Dwyer, and Mai Q. Nguyen

regional or distant metastatic CSCC. Those most commonly used are cisplatin, carboplatin, and 5-FU, either as monotherapy or combination regimens. 66 – 76 For the 2022 update, the panel voted to include carboplatin ± paclitaxel under options useful in

Full access

Current Concepts in Penile Cancer

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole

chemotherapy. 47 Based on a patient’s response to systemic chemotherapy (ie, stable disease, partial or complete response), surgical consolidation may be considered thereafter. Pagliaro et al 42 recently reported that neoadjuvant chemotherapy with paclitaxel

Full access

Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

(response rate, 32% vs 9%; median OS, 11.1 vs 6.8 months, respectively) in a group of patients with metastatic PCA. 5 More recently, the combination of gemcitabine and nab-paclitaxel has likewise proven to be superior to gemcitabine alone for patients with

Full access

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development

Talia Golan and Milind Javle

months with combination therapies (gemcitabine/nab-paclitaxel or FOLFIRINOX). 3 , 4 Despite numerous phase II/III studies of PDAC in the past decade, treatment options remain limited. 5 Advances in other solid tumors have been possible due to biomarker

Full access

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

regimens included (1) cisplatin + either pemetrexed (nonsquamous only) or gemcitabine (squamous only); or (2) carboplatin + paclitaxel (any histology). If their patients could not tolerate cisplatin, clinicians could substitute carboplatin-based regimens

Full access

HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers

Samuel L. Cytryn and Yelena Y. Janjigian

-label phase II trial demonstrated superior efficacy of T-DXd compared with physician’s choice of paclitaxel or irinotecan, with improvements across all metrics, including ORR (51% vs 14%), as well as median PFS and OS (5.6 vs 3.5 months and 12.5 vs 8.4 months

Full access

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Jonathan L. Wright, Lisa A. Gurski, and Alyse Johnson-Chilla

urothelial bladder cancer. 115 – 118 Based on these results, several groups are exploring 2- and 3-drug combinations using these agents, with and without cisplatin. A randomized phase III trial was conducted to compare GC and GC plus paclitaxel in 626

Full access

Community Oncologists' Decision-Making for Treatment of Older Patients With Cancer

Supriya G. Mohile, Allison Magnuson, Chintan Pandya, Carla Velarde, Paul Duberstein, Arti Hurria, Kah Poh Loh, Megan Wells, Sandy Plumb, Nikesha Gilmore, Marie Flannery, Marsha Wittink, Ronald Epstein, Charles E. Heckler, Michelle Janelsins, Karen Mustian, Judith O. Hopkins, Jane Liu, Srihari Peri, and William Dale

single-agent chemotherapy, such as gemcitabine or capecitabine, and 35.4% (n=57) would offer multiagent chemotherapy, such as FOLFIRINOX or gemcitabine/nab-paclitaxel. Bivariate Analyses: A consistent relationship was seen between vignette

Full access

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson III, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer Jr., Robert A. Wolff, Brian M. Wolpin, Beth Lynn, and Giby V. George

patients with good performance status. 149 , 150 , 152 Gemcitabine Plus Albumin-Bound Paclitaxel Albumin-bound paclitaxel is a nanoparticle form of paclitaxel. In a publication of a phase I–II trial, 67 patients with advanced pancreatic cancer